BioSyent
- Company typePublic
- Founded2026
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
BioSyent firmographics
Firmographics- Name
- BioSyent
- Legal name
- BioSyent Inc.
- Website
- https://biosyent.com
- Company type
- Public
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BioSyent industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
- akta.pro secondary industries
- Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where BioSyent is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
BioSyent business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Marketing or Sales, Personnel, Operations, Supply Chain
Revenue model
- Pharmaceutical Products: Sale of prescription and over-the-counter pharmaceutical products including FeraMAX iron supplements, Tibelia, Inofolic, and other products marketed through Canadian pharmacies and healthcare providers.
- Oral Health Products: Revenue from oral health products following the Oral Science acquisition, including dental hygiene and specialized oral health products distributed in Canada.
- Thyconvi (Levothyroxine): BioSyent Pharma holds exclusive license rights to register, market, sell, and distribute Thyconvi across Canada, expanding into endocrinology therapeutic area.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Products sold at standard retail pharmacy pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
BioSyent product offering
Product offeringCore offering
BioSyent is a Canadian specialty healthcare company that sources, in-licenses, acquires and further develops innovative pharmaceutical and oral health products. It commercializes a portfolio of prescription and OTC brands — including FeraMAX iron supplements, Inofolic for PCOS, Tibelia hormonal therapy, RepaGyn, Gelclair, Cathejell, Proktis-M and the newly approved Thyconvi levothyroxine oral solution — distributing them in Canada through a national sales team and pharmacies, with secondary international distribution in Latin America, Asia-Pacific and Africa.
Product overview
BioSyent is a specialty healthcare company operating a diversified portfolio of pharmaceutical and consumer health products across multiple therapeutic areas. The core platform consists of prescription and OTC products organized by therapeutic focus: iron health (FeraMAX line with Pd, Pd Maintenance 45, and Pd Powder 15 formulations), women's health (Inofolic for PCOS, Tibelia hormonal therapy), wound healing (RepaGyn and Proktis-M with hyaluronic acid), oncology supportive care (Gelclair), and anesthetics (Cathejell MD). The March 2026 acquisition of Oral Science expanded the portfolio into dental health products. A significant new launch is Thyconvi, the first Health Canada-approved levothyroxine oral solution for hypothyroidism, marking entry into endocrinology. The company markets approximately 10 approved products through community, specialty, and international commercial units.
Differentiator
Problem solved
Functional benefit
Brands
- FeraMAX: Over-the-counter iron supplement brand, Canada's top-recommended OTC iron supplement for 11 consecutive years. Includes FeraMAX Pd, FeraMAX Pd Maintenance 45, and FeraMAX Pd Powder 15 products.
- Thyconvi
- Inofolic
- RepaGyn
- Gelclair
- Cathejell
- Proktis-M
- Tibelia
Products and services
- FeraMAX Pd 150 mg Prescription-strength oral iron supplement using BioSyent's proprietary polydextrose-iron complex (PDIC) to deliver 150 mg of elemental iron for treating iron deficiency anemia in adults.
- FeraMAX Pd Maintenance 45 Chewable iron supplement with 45 mg elemental iron plus 75 mg vitamin C and 1000 mcg vitamin B12 for preventing iron deficiency anemia and supporting normal iron levels.
- FeraMAX Pd Powder 15 Pediatric iron supplement powder delivering 15 mg elemental iron per dose for infants and children ages 3 and up to prevent iron deficiency and anemia.
- Inofolic Myo-inositol and folic acid supplement for women with Polycystic Ovary Syndrome (PCOS), supporting menstrual cycle regulation, ovulation and fertility outcomes.
- Thyconvi (levothyroxine sodium oral solution) Levothyroxine sodium oral solution approved by Health Canada for managing hypothyroidism and thyroid-stimulating hormone suppression — the first levothyroxine oral solution available in Canada.
- Tibelia Hormonal therapy product generating $2.4 million in international sales in 2025, distributed across BioSyent's emerging-market commercial operations.
- RepaGyn Vaginal suppositories containing 5 mg hyaluronic acid per 2 g suppository for relieving vaginal dryness and promoting mucosal healing.
- Gelclair Oncology supportive care gel that forms a protective film when used as a mouthwash to relieve painful symptoms of oropharyngeal mucositis from medication, disease, radiotherapy, chemotherapy or oral surgery.
- Cathejell MD Topical 2% w/w lidocaine anesthetic gel for temporary numbing of skin prior to examinations and to relieve pain associated with bladder and urethral inflammation.
- Proktis-M Rectal suppositories containing 5 mg hyaluronic acid per 2 g suppository for promoting healing of the anus and rectum.
- Oral Science dental hygiene and oral health product line Line of dental hygiene and oral health products distributed to Canadian dental professionals through Oral Science Inc., the wholly-owned subsidiary acquired by BioSyent in March 2026.
Quantifiable outcome
- 23% revenue growth in FY 2025 to $43.1 million
- +3 more outcomes
Companies that use BioSyent
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles4 records
BioSyent technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
BioSyent partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Oral Science Inc. (Acquired)corePrivately-owned Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard, Quebec. Acquired for $25.5 million including cash, shares, earn-outs and royalties. Continues operating as standalone business unit with founding leadership team retained.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
BioSyent competitors and assessment
Company assessmentOthers
- Cardinal Health: Major U.S. healthcare distributor and manufacturer; prior employer of BioSyent's VP & GM Marnie McCormick, who led marketing and product management for Cardinal Health Canada's large distribution business. Distribution model overlaps with BioSyent's pharmacy-channel GTM but at vastly larger scale.
- McKesson Canada: Canada's largest pharmaceutical distributor, serving the same Canadian pharmacy networks that BioSyent relies on for FeraMAX, Tibelia and other products. Functions as an indirect channel partner rather than a direct competitor but shapes the economics of BioSyent's distribution.
Direct peers
- Cipher Pharmaceuticals: Canadian specialty pharma company focused on dermatology, women's health, and hospital products through in-licensing and acquisition. Directly comparable to BioSyent's commercial-stage, niche-therapeutic strategy and TSX Venture listing.
- Acerus Pharmaceuticals: Canadian specialty pharma commercializing products in men's health, women's health, and endocrinology. Comparable in size, structure, and Canadian specialty pharma model; shares BioSyent's endocrinology and women's health therapeutic focus.
- Paladin Labs: Canadian specialty pharmaceutical company founded by Jonathan Ross Goodman (now Knight Therapeutics) focused on acquiring and licensing innovative products for Canadian and emerging markets. Provides a direct historical analogue to BioSyent's niche-licensing commercial model.
- Knight Therapeutics: Canadian specialty pharmaceutical company that acquires, in-licenses and markets innovative products across Latin America and other international markets. Closely mirrors BioSyent's commercial model of sourcing proven products globally and distributing through specialty channels, with a larger scale and similar therapeutic-area breadth.
- Searchlight Pharma: Privately-held Canadian specialty pharmaceutical company that in-licenses and markets women's health, dermatology and other niche products in Canada. Closely mirrors BioSyent's therapeutic portfolio emphasis on women's health and commercial-stage specialty model.
- HLS Therapeutics: Canadian specialty pharmaceutical company that acquires and commercializes late-stage products, primarily in CNS and cardiovascular. Similar in-licensing/M&A growth playbook and Canadian GTM to BioSyent, though focused on different therapeutic categories.
Broad incumbents
- Bausch Health Companies: Large Canadian-listed specialty pharma with diversified therapeutic portfolio including women's health, neurology, and dermatology. Much larger and broader in scope than BioSyent but operates in overlapping therapeutic categories through similar specialty-pharmacy channels.
- Tilray Brands: Canadian-listed company with pharmaceutical operations in addition to cannabis, distributing specialty health products through Canadian pharmacy and healthcare channels. Competes for capital and distribution shelf space but operates a much broader and less focused portfolio than BioSyent.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioSyent social profiles
Digital presenceBioSyent financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioSyent leadership team
Management profileNumber of profiles
Profiles14 records
BioSyent subsidiaries and ownership
Company hierarchySubsidiaries2 records
BioSyent funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioSyent M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioSyent
What does BioSyent do?
BioSyent is a Canadian specialty healthcare company that sources, in-licenses, acquires and further develops innovative pharmaceutical and oral health products. It commercializes a portfolio of prescription and OTC brands — including FeraMAX iron supplements, Inofolic for PCOS, Tibelia hormonal therapy, RepaGyn, Gelclair, Cathejell, Proktis-M and the newly approved Thyconvi levothyroxine oral solution — distributing them in Canada through a national sales team and pharmacies, with secondary international distribution in Latin America, Asia-Pacific and Africa.
Is BioSyent a public or private company?
BioSyent is a public company. It is classified as public and is currently operating.
When was BioSyent founded?
BioSyent was founded in 2026. It employs 11 to 50 people.
Where is BioSyent based?
BioSyent is headquartered in Toronto, Canada, in the North America region.
How does BioSyent make money?
Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are oral Health Products and thyconvi (Levothyroxine).
Who are BioSyent's main competitors?
Others on record are Cardinal Health and McKesson Canada. Direct peers are Cipher Pharmaceuticals, Acerus Pharmaceuticals, Paladin Labs, Knight Therapeutics, Searchlight Pharma and HLS Therapeutics. Broad incumbents are Bausch Health Companies and Tilray Brands.
Does BioSyent have an API?
No public API is recorded for BioSyent.
What industry is BioSyent in?
BioSyent's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.